The release of Phase 2 data is a critical milestone for biotech companies like Cybin. Positive results can lead to increased investor confidence and a potential surge in stock price, while negative results could have the opposite effect. Given that the data is for a major indication like Major Depressive Disorder, the impact on the stock could be significant. The R&D briefing will also provide investors with a deeper understanding of the drug's potential and the company's direction, which can further influence the stock's performance.